SCHEMBL3285536

SCHEMBL3285536

COc1ccc(CNc2nc(NCCOCCNC(=O)OC(C)(C)C)nc(NCc3ccc(OC)cc3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
VNN1 O95497 1/20 0.43
SUCNR1 Q9BXA5 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HSP90AA1 P07900 1/20 0.42
GAA P10253 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
EPHX2 P34913 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
BRD4 O60885 2/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13326022 0.99 ADORA2A (0.47) ADORA2AADORA1CA12CA1CA2
SCHEMBL3285533 0.83 ALDH1A1 (0.43) VNN1ALDH1A1HSP90AA1GAATP53
SCHEMBL3120956 0.78 CTNNB1 (0.51) NPC1RAB9AKMT2AMEN1BRD4
SCHEMBL2843448 0.78 L3MBTL1 (0.46) CA12CA1CA2CA9VNN1
SCHEMBL7652554 0.78 NPC1 (0.58) ALDH1A1GAANPC1RAB9AKMT2A
SCHEMBL21066545 0.77 KMT2A (0.52) CA1CA2ALDH1A1NPC1RAB9A
SCHEMBL2955788 0.77 ADORA2A (0.43) ADORA2AADORA1BRD4
SCHEMBL18086456 0.76 NPC1 (0.56) CA12CA1CA2CA9SUCNR1
SCHEMBL13326031 0.76 BCDIN3D (0.50) ALDH1A1GAANPC1RAB9AKMT2A
SCHEMBL21070067 0.76 ACHE (0.56) CA12CA1CA2CA9SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718655-B2 Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity NEW YORK UNIVERSITY (US) 2010-05-18 US disclosed
US-20040122009-A1 Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity NEW YORK UNIVERSITY (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122009-A1 Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity TUBA1C, TUBB1, TUBB ADORA2A 4848/4885ADORA1 4865/4885CA12 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.